News Archive - SMA Europe

The purpose of SMA Europe is to provide a framework to stimulate collaboration and accelerate translational research pathways in SMA and promote patient care.

  1. Roche provides community update on FIREFISH & SUNFISH studies of risdiplam

    Roche has provided us with the following statement on the FIREFISH and SUNFISH studies of risdiplam: Dear SMA community, We are happy to share an update on our FIREFISH and SUNFISH studies of risdiplam. We would also like to acknowledge the tremendous support and partnership of SMA Patient Groups around the world and to thank […]

    READ MORE

  2. Biogen provides information on upcoming Spinraza EU label

    In response to our request, Biogen has provided us with information and addressed our questions and concerns regarding the upcoming SPINRAZA (nusinersen) EU label (Prescribing information and Package Leaflet) update that will include information on the potential risk of hydrocephalus. All medicines are evaluated for the benefit they provide to patients as well as the […]

    READ MORE

  3. RG7916 community update from Roche

    Roche has shared with us an update of the RG7916, now called risdiplam, programme, which has reached a number of milestones. Risdiplam is an SMN2 splicing modifier which is given daily by mouth or by g-tube as a liquid and distributes widely throughout the body. Risdiplam has been designed to help the SMN2 gene produce more […]

    READ MORE

  4. Novel protective gene for SMA opens new therapeutic options

    The research group of Prof. Dr. Brunhilde Wirth, Head of the Institute of Human Genetics at the University Hospital Cologne and Chair of our Scientific Advisory Board, succeeded to identify calcineurin-like EF-hand Protein 1 (CHP1) reduction as a novel protective modifier for SMA. The results of this study have been published in Brain, an international highly renowned journal. […]

    READ MORE